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ABSTRACT
Introduction: Patient eczema severity time
(PEST) is a new atopic dermatitis (AD) scoring
system based on patients’ own perception of their
disease. Conventional scales such as SCORing of
atopic dermatitis (SCORAD) reflect the clinician’s
observations during the clinic visit. Instead, the
PEST score captures eczema severity, relapse and
recovery asexperiencedbythe patientorcaregiver
on a daily basis, promoting patient engagement,
compliance with treatment and improved out-
comes. This study aims to determine the correla-
tion between carer-assessed PEST and
clinician-assessed SCORAD in paediatric AD
patients after 12 weeks of treatment using a
ceramide-dominant therapeutic moisturizer.
Methods: Prospective, open-label, observa-
tional, multi-centre study in which children with
AD aged 6 months to 6 years were treated with a
ceramide dominant therapeutic moisturizer
twice daily for 12 weeks; 58 children with
mild-to-moderate AD were included. Correlation
between the 7-day averaged PEST and SCORAD
scores for assessment of AD severity was mea-
sured within a general linear model. PEST and
SCORAD were compared in week 4 and week 12.
Results: At week 12, a moderate correlation was
found between the SCORAD and PEST scores
(r = 0.51). The mean change in SCORAD and
PEST scores from baseline to week 12 was
-11.46 [95% confidence interval (CI) -14.99 to
-7.92, p\0.0001] and -1.33 (95% CI -0.71 to
-0.10, p\0.0001) respectively. PEST demon-
strated greater responsiveness to change (33.3%
of scale) compared to SCORAD (13.8% of scale).
Conclusion: The PEST score correlates well with
the SCORAD score and may have improved sen-
sitivity when detecting changes in the severity of
AD. The ceramide-dominant therapeutic
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INTRODUCTION
Atopic dermatitis (AD) is a chronic, relapsing
inflammatory skin disorder with onset com-
monly occurring in infancy and childhood [1–3].
AD-prone patients may develop allergic rhinitis,
food allergy and asthma [1, 4–6]. AD arises as a
result of a complex interaction of environmental
and genetic factors. Breakdown of the skin barrier
is common to all forms of AD. At the mild end of
the severity spectrum, this predominantly arises
as a result of outside-inside interactions, while at
the severe end of the spectrum, it is predomi-
nantly inside-outside with immune dysregula-
tion playing a major role [1, 7]. Meanwhile, there
is increasing evidence supporting a barrier-initi-
ated pathogenesis of AD [7–10].
The severity of AD can be assessed using vari-
ous scoring systems such as the scoring of atopic
dermatitis index (SCORAD), eczema area and
severity index (EASI) and patient-oriented
eczema measure (POEM), each of which is sensi-
tive and widely accepted [11–14]. SCORAD was
developed by the European Task Force on Atopic
Dermatitis (ETFAD) [15] to assess the extent and
severity of AD. Considered an objective measure,
SCORAD’s strengths include its validity, respon-
siveness and inter-observer reliability. Its limita-
tions were previously reported [13, 16, 17].
Patient eczema severity time (PEST) is a new,
simple daily measure, which supports the
patients’ own perception and experience of the
severity of their disease [18]. Patients or carers rate
the severity of AD on a daily basis, thus reflecting
disease fluctuations over a period of time instead
of at discrete time intervals. Such insights may
promote effective management of AD.
This study sought to investigate thecorrelation
between SCORAD and PEST scores over 12 weeks
in children between 6 months and 6 years of age.
METHODS
Study Design
This was a prospective, open-label, single-arm,
observational and multicentre study.
Study Population
Patients were recruited from two centres in
Singapore. Male and female children between
6 months to 6 years of age, with evidence of
mild to moderate AD, as determined by der-
matitis with baseline PEST scores of 3–4, and
grading of 3–11 as per the Nottingham
Eczema Severity Scale (NESS), were eligible.
Other inclusion criteria were diagnosis of
current flare (increased dryness, itching, red-
ness, swelling and general irritability) at the
baseline visit according to the investigator’s
judgement and dermatologist-naı¨ve for treat-
ment of AD. Informed consent was obtained
from the parent or guardian (and assent as
well, if applicable).
Patients with clinical signs of skin infection,
history of severe episodes of AD, known reac-
tion or allergy to the test drug, excipients,
steroids, history of cutaneous or systemic dis-
eases or medication that might interfere in the
study results were excluded from study.
Procedure
Participants received treatment with a
ceramide-dominant therapeutic moisturizer
(Ceradan Cream; Hyphens Pharma Pte Ltd,
Singapore) for topical application at least twice
daily for 12 weeks. Use of permitted topical
steroid(s) as rescue treatment was allowed
according to standard local practice and
according to investigator discretion. A non--
soap based wash once or twice daily was also
allowed during the study period. Patients were
evaluated for severity of AD at baseline, week 4
(visit 2) and week 12 (visit 3) using SCORAD.
PEST was recorded daily using a patient diary
containing pictorials ranging from ‘not at all
unhappy’ to ‘extremely unhappy’ and scoring
1–5 (Fig. 1).
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Outcome Measures
The primary outcome was the correlation
between the PEST and SCORAD scores after
12 weeks of treatment. Secondary outcomes
included changes in SCORAD and PEST scores
during follow-up, progress of AD over time eval-
uated by changes in SCORAD and PEST scores,
and counts of relapse or flare of AD. Using
SCORAD as a basis, the severity grading was
defined as mild (\20), moderate (20–40) and
severe (C40). Relapse was defined as exacerbation
of AD to the level where a topical corticosteroid
or alternative therapy was required.
The study also evaluated subject satisfaction.
At the end of the study (week 12), patients were
asked whether they would like to continue with
the emollient regimen. Options tochoosewere (1)
definitely, (2) most likely, (3) maybe and (4) no.
Adverse Events
All treatment-emergent adverse events (TEAEs)
were recorded at each study visit. Number, dose
and duration of rescue medications used for
adverse events were also documented.
Sample Size
Sample size was determined by considering an
anticipated correlation of 0.4 between the mean
PEST and SCORAD scores providing 80% power
at a 5% significance level, applying Fisher’s
z test for Pearson correlation. Thus, 46 evaluable
patients were required.
Statistical Analyses
Pearson’s correlation (r) between PEST and
SCORAD scores at week 12 was estimated using
a general linear model (GLM) of standardized
scores. Values of |r| C 0.5 signified moderate
correlation and |r| C 0.7 signified high correla-
tion. PEST scores were averaged over the 7-day
period corresponding to the 1-week recall of the
SCORAD, e.g. the 4th or 12th week. For con-
tinuous variables, descriptive statistics were
presented as counts, mean, median, standard
deviation, minimum and maximum. Categori-
cal variables were presented as counts and
percentages.
For patients who were withdrawn early from
the study, analyses conservatively applied the
last observation carried forward principle. The
primary analysis was by modified intention to
treat (mITT), although efficacy was also explored
as patients completing treatment per protocol
and excluding patients with major protocol
deviations. Safety was assessed for all patients
who applied the study medication at least once.
All statistical analyses were performed with SAS
version 9.2 or higher.
This study was approved by the institutional
review board (IRB) of KK Women’s and Chil-
dren’s Hospital and National Skin Centre Sin-
gapore and conducted according to Good
Clinical Practice guidelines and applicable local
regulatory requirements. All procedures fol-
lowed were in accordance with the ethical
standards of the Helsinki Declaration of 1964, as
revised in 2013. Written informed consent was
obtained from all patients or their caregivers.
Fig. 1 PEST scoring tool. PEST patient eczema severity time
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RESULTS
Subjects
A total of 58 subjects were screened between
March 2014 and August 2014. All subjects
received a ceramide-dominant therapeutic
moisturizer at least twice daily for 12 weeks. Ten
subjects were withdrawn prematurely for a range
of reasons, although all contributed to the safety
analysis (Fig. 2). The modified intent-to-treat
population consisted of 55 (94.8%) patients: 3
patients had five major protocol deviations of the
following nature: three counts of eligibility cri-
teria violation, one incomplete patient diary and
one missing diary. The most common minor
deviation was follow-up attendance outside of
the acceptable window period: 13 patients for
visit 2 and 11 patients for visit 3. The per-protocol
population included 46 (79.3%) patients.
Subjects’ age ranged from 0.5 to 6.4 years;
48.3% were male and 51.7% were female. The
majority of subjects were Chinese (79.3%). At
baseline, the mean SCORAD score was 24.4 (8.5
SD) and mean PEST score was 3.11 (0.52 SD) for
the mITT population with the last observation
carried forward (LOCF) (Table 1).
Correlation Between PEST and SCORAD
Scores
The primary finding was a moderate correlation
between the SCORAD and PEST score (r = 0.51)
at week 12 (Fig. 3). Correlation was similar at
week 4 (r = 0.52), but at baseline, the correlation
was weak (r = 0.22) (Table 2). Analysis of
All 58 Subjects were 
eligible and allocated 
Ceramide-dominant 
therapeutic moisturizer
10 Subjects prematurely 
discontinued
48 Subjects completed 
study
Withdrawal of 
consent (N=5)
Subject protocol 
eligibility violation 
(N=1)
Subject non-
compliance (N=2)
Subject lost to 
follow up (N=2)
Enrollment 
Phase
Screening 
Phase
Treatment 
Phase
Total 58 Subjects 
screened
•
•
•
•
Fig. 2 Flow diagram of subject disposition
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correlation stratified by level of ceramide-domi-
nant therapeutic moisturizer usage at week 12
showed moderate correlation (r = 0.48) in the
lowest range of therapeutic moisturizer used
(20–399.99 g). The use of more therapeutic
moisturizer showed higher correlation, i.e.
400–799.9 g (r = 0.50) and 800–1200 g (r = 0.71).
Efficacy by Change in SCORAD and PEST
Scores
SCORAD decreased from the baseline during the
study period. Mean change from baseline was
-8.63 (95% CI -11.68 to -5.57) and -11.46
(95% CI -14.99 to -7.92) at visit 2 and visit 3
respectively; both changes were statistically
significant (p\0.0001). Mean PEST decreased
from baseline by -0.93 (95% CI -1.18 to -0.67)
at visit 2 (average score of 2.2) and -1.33 (95%
CI -1.62 to -1.04) at visit 3 (average score of
2.0); both changes were statistically significant
(p\0.0001).
The mean change in SCORAD, with a range
of 0–83, was 13.8% of scale (95% CI 9.5–18.1%);
the mean change in PEST (with a range of 1–5)
was 33.3% of scale (95% CI 26.0–40.5%).
Changes in PEST Score Over Time
All subjects started with scores of 3 or 4 (quite
and very unhappy); improvement in the sever-
ity of AD was observed over time (Fig. 4). After
12 weeks of treatment, of 48 patients in the
quite unhappy category at baseline, 39 (81.3%)
showed improvement in AD severity, 3 (6.25%)
observed no change in AD severity and 4
(8.33%) showed worsening in AD severity; 2
(4.17%) patients’ records were not available. Of
the seven patients who were very unhappy at
baseline, after 12 weeks of treatment, all of the
patients showed improvement in AD severity:
four (57.1%) patients were found in the not at
all unhappy group, one (14.3%) patient was in
the a little unhappy and two (28.6%) patients
were in the quite unhappy category; none of the
subjects were reported as very unhappy or
extremely unhappy.
Changes in the SCORAD Score over Time
Subjects using the ceramide-dominant thera-
peutic moisturizer showed general improve-
ment in AD (Fig. 5). None of the patients’
severity had worsened from the mild to severe
category after 12 weeks of treatment. Thirty--
three subjects with a moderate AD category
either improved to the mild category (26 sub-
jects) or remained in the moderate category (6
subjects), while one patient showed increased
severity from moderate to severe AD after
12 weeks of treatment. Two subjects with the
severe category at baseline showed
Table 1 Demographic and disease characteristics at
baseline
Variable N5 58
Mean age in years
(range in years)
2.61 (0.51–6.44)
Number
of subjects
%
Gender
Male 28 48.28
Female 30 51.72
Race
Chinese 46 79.31
Malay 6 10.34
Indian 3 5.17
Others 3 5.17
Height (cm): mean (SD) 89.82 (17.06)
Weight (kg): mean (SD) 13.01 (4.60)
SCORAD score for mITT
population with LOCF
(N = 55) at baseline
mean (SD)
24.42 (8.46)
PEST score for mITT
population with LOCF
(N = 55) at baseline
mean (SD)
3.11 (0.52)
cm centimetres, kg kilograms, SD standard deviation,
mITT modiﬁed intention to treat
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improvement in AD severity; one subject was
found to be in the mild AD category, and
another was found to be in the moderate AD
category.
Relapse of AD
Use of the ceramide-dominant therapeutic
moisturizer prevented relapse of AD in 25
(45.5%) patients.
Subject Satisfaction
More than half of the patients, 32 (58.2%),
indicated that they would like to continue the
use of the ceramide-dominant therapeutic
moisturizer regimen, 15 (27.3%) patients
responded that they may continue with the
ceramide-dominant therapeutic moisturizer
and only 2 (3.6%) patients answered that they
would not use this regimen (Table 3).
Safety
During the study, 26 (44.8%) patients reported
at least one adverse event (AE). Overall, 40 AEs
were reported (Table 4); none were reported as
severe. The causality of the AEs was categorized
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Fig. 3 Scatter plot of the SCORAD score vs. PEST score
at visit 3 (week 12) with 95% CI. PEST patient eczema
severity time, SCORAD scoring of atopic dermatitis, mITT
modiﬁed intention-to-treat, LOCF last observation carried
forward, CI conﬁdence interval
Table 2 Correlation between the PEST and SCORAD
scores at baseline, week 4 and week 12 (mITT population
with LOCF imputation)
(N5 55)
n
Correlation
coefﬁcient
Visit 1 (baseline) 54 0.22
Visit 2 (week 4) 53 0.52
Visit 3 (week 12) 43 0.51
Correlation coefﬁcient calculated from the generalized linear
model
PEST patient eczema severity time, SCORAD scoring of
atopic dermatitis, mITT modiﬁed intention to treat,
LOCF last observation carried forward, N number of
subjects in the mITT population, n number of subjects in
the speciﬁed category
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as ‘certain/definite, probable, possible, unlikely
and not related’ to the use of the
ceramide-dominant therapeutic moisturizer.
Two (3.45%) of the patients had ‘probable’ AEs,
none of the patients had experienced ‘possible’
AEs and two (3.45%) of the patients had ‘un-
likely’ AEs, while the remaining 23 (39.66%)
patients experienced ‘not related’ AEs. The most
common AEs reported are respiratory disorders
and skin disorders. No death was reported in
this study. One patient was discontinued from
treatment because of AE/SAE. Only one SAE, a
viral infection, occurred in one (1.72%) patient,
and this was evaluated to be not related to the
use of the ceramide-dominant therapeutic
moisturizer.
DISCUSSION
Charman and colleagues revealed that use of
valid and clinically meaningful patient out-
come measures is gaining importance as more
stress is being placed on the results of patient/-
carer measures in clinical trials [19]. Clinical
assessments of disease may be inadequate to
express disease impact, and subjective measures
may help to provide a more complete and
appropriate assessment of the effect of treat-
ment on patients’ lives [12, 20]. Mason and
colleagues reported a new patient-centric scor-
ing system, PEST for assessment of atopic der-
matitis [18]. PEST is a simple system, which
assesses a patient’s (or carer’s) global feeling
about the severity of disease instead of clinical
opinion, while its ease of use as a daily record
allows important changes over time to be cap-
tured. The pictorial design helps the parents to
assess the PEST score in patients who are too
young to vocalize their own experience.
PEST was used concurrently with POEM in
an educational programme aimed at increasing
emollient use and reducing AD symptoms in
136 children aged 3 months to 6 years with
mild to moderate atopic eczema [18]. The POEM
scale uses a questionnaire of seven questions,
each with a 5-point scale (0–4) to assess symp-
tom frequency and the pattern of remission and
relapse. Topical emollient application reduced
AD severity: on average, the POEM score
reduced by 5.38 (95% CI 4.36–6.41, p = 0.001),
a 47% reduction from baseline, while the PEST
score reduced by 0.61 (95% CI 0.47–0.75,
p = 0.001), a 48% reduction from baseline.
POEM and PEST scores were strongly correlated
with Pearson correlation coefficients. At week
2.8
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Fig. 4 Progress of the condition using an average PEST score per week over 12 weeks. PEST patient eczema severity time
Dermatol Ther (Heidelb)
12, the correlation coefficient was 0.71
(p\0.01). While POEM assesses and aggregates
the frequency of signs and symptoms experi-
enced in the past week, PEST captures changes
over time of the summative experience of the
patient. Thus, a major advantage of the PEST
score is that it takes only a couple of seconds for
the patient/carer to give a score.
In the present study, we evaluated the use of
SCORAD and PEST scores in the management of
Fig. 5 Progression of the condition of AD using the SCORAD score over week 12 of the time-mITT (LOCF) population.
SCORAD scoring of atopic dermatitis, mITT modiﬁed intention-to-treat, LOCF last observation carried forward
Table 3 Subject satisfaction with the ceramide-dominant
therapeutic moisturizer at week 12
Subject satisfaction for
ceramide-dominant therapeutic
moisturizer
(N5 55)
n (%)
Deﬁnitely ? most likely 32 (58.18%)
Maybe 15 (27.27%)
No 2 (3.64%)
Not available 6 (10.91%)
N number of subjects in the mITT population, n number
of subjects at the speciﬁed category
Table 4 Overall summary of adverse events
Category (N5 58)
n (%)
Total number of adverse events (AE) 40
Total number of subjects
with at least one AE
26 (44.83%)
Total number of serious adverse
events (SAE)
1
Total number of subjects
with at least one SAE
1 (1.72%)
Death 0 (0.00%)
Subjects discontinued because of AE/SAE 1 (1.72%)
Mild 24 (41.38%)
Moderate 3 (5.17%)
Severe 0 (0.00%)
None of the patients experienced AE that was ‘certainly/
deﬁnitely’ related to the ceramide-dominant therapeutic
moisturizer
N number of subjects in the safety population, n number
of subjects at a speciﬁed category
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AD in children aged 6 months to 6 years who used
a ceramide-dominant therapeutic moisturizer.
SCORAD and PEST scores were moderately cor-
related at week 4 (r = 0.52) and at week 12
(r = 0.51), providing some cross validation,
although the two measures may be capturing
different aspects of the disease. SCORAD pro-
vides detailed clinical assessments at a point in
time; PEST describes and summates the
time-varying patient experience of AD. Interest-
ingly, the weak correlation at baseline could be
due to a disconnect between an objective scoring
(SCORAD) and patient score when there is acute
flare. This phenomenon could be unique in Sin-
gapore where patients are generally demanding,
resulting in them giving higher PEST scores than
the corresponding SCORAD score.
Also, the proportionate scale changes suggest
the discrimination provided by daily assessment
may make PEST a more sensitive measure with
greater proportionate use of the scale range.
In contrast, SCORAD is not used as a daily
measure, but is used to characterise the area and
intensity of AD with minor weight given to the
patient experience. Individual patients may
only use a small part of its range of scores, e.g.
mild disease. Thus, the sensitivity of SCORAD is
constrained by the frequency of use and area of
involvement. However, in contrast to PEST,
SCORAD remains useful to compare severity
between patients and individual patient chan-
ges during a clinical trial.
PEST, as a patient-reported outcome measure
(PROM), may have particular utility as a sensi-
tive measure for use in the clinic or clinical trials
because of its range and time characteristics. The
score range expands to fit an individual patient:
score 1 is the best the AD is for that individual
patient; score 5 is the worst it is for that indi-
vidual patient. In the time domain, PEST has the
ability to capture the relapsing-remitting nature
of AD as experienced by the patient (or their
carer) on a daily basis and thus is important in
the long-term management.
The study was designed to recruit patients
with current flares; thus, topical steroid(s) were
used to rapidly control the inflammation. The
European Guidelines for treatment of atopic
dermatitis clearly state that emollient use alone
on inflamed skin is poorly tolerated and
recommend treating the acute flare first [21].
Therefore, one possible limitation is that the
effect of the steroid on PEST in the early days
cannot be ruled out. Hence, the degree of
severity improvement in the early days must be
interpreted carefully.
CONCLUSIONS
The PEST score correlates moderately with the
SCORAD score and has improved sensitivity
when detecting changes in the severity of AD in
an individual patient in a clinical trial or in the
clinic. Measuring the PEST score daily may
provide insights for better patient prognosis and
concordance. The ceramide-dominant thera-
peutic moisturizer used within the study was
safe and effective in the management of AD in
young children.
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